Industry and regulators clash in debate over trial data disclosure
This article was originally published in Scrip
Executive Summary
Sparks flew at a recent debate in Brussels where representatives of the European Medicines Agency and the pharmaceutical industry sparred over the best way to disclose clinical trial data. While it was evident that both want to reach a mutually acceptable solution and are prepared to give some ground, the 27 August event showed there are still many fundamental differences over what data should be proactively released, by whom, and in what way.